PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0851-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of	995, no persons are required to respond to a colle-	ction of information unless it displays a valid OMB control number				
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER PC26188A				
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
INTERNATIONAL APPLICATION NO. PCT/IB2005/000258	INTERNATIONAL FILING DATE February 1, 2005	PRIORITY DATE CLAIMED February 11, 2004				
TITLE OF INVENTION Therapeutic Amid	e Derivatives					
APPLICANT(S) FOR DO/EO/US KAWAI, M	akoto; KAWAMURA, Mitsuhiro, MORITA	A, Asato; SAKURADA, Isao				
Applicant herewith submits to the United S	tates Designated/Elected Office (DO/E	O/US) the following items and other information:				
This is a FIRST submission of items	concerning a submission under 35 U.S.C. 37	1.				
2. This is a SECOND or SUBSEQUENT	submission of items concerning a submission	on under 35 U.S.C. 371.				
This is an express request to begin not (5), (6), (9) and (21) indicated below.	ational examination procedures (35 U.S.C. 37	71(f)). The submission must include items				
4. In The US has been elected (Article 31)						
5. A copy of the International Applicati	on as filed (35 U.S.C. 371(c)(2))					
a. is attached hereto (require	<ul> <li>a.  is attached hereto (required only if not communicated by the International Bureau).</li> </ul>					
b. has been communicated I	by the International Bureau.					
c. is not required, as the app	lication was filed in the United States Receiv	ing Office (RO/US).				
6. An English language translation of t	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).					
<ul> <li>a. is attached hereto.</li> </ul>						
	b. has been previously submitted under 35 U.S.C. 154(d)(4).					
7. Amendments to the claims of the In	ernational Application under PCT Article 19	(35 U.S.C. 371(c)(3))				
a. are attached hereto (requ	<ul> <li>are attached hereto (required only if not communicated by the International Bureau).</li> </ul>					
b. have been communicate	b.  have been communicated by the International Bureau.					
c. have not been made; ho	c. have not been made; however, the time limit for making such amendments has NOT expired.					
d. 🗹 have not been made and	d. I have not been made and will not be made.					
8. An English language translation of	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
An oath or declaration of the inventor	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
Article 36 (35 Ú.S.C. 371(c)(5)).						
Items 11 to 20 below concern document(	s) or information included:					
11. An Information Disclosure Statemen	t under 37 CFR 1.97 and 1.98.					
F271	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
	A preliminary amendment.					
	An Application Data Sheet under 37 CFR 1.76.					
15. A substitute specification.						
_	A power of attorney and/or change of address letter.					
	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.					
	A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
<ol> <li>A second copy of the English langua</li> </ol>	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).					

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2077, OMB 051-0021
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
ICATION NO. (If known 1995 To FEP 4 to 1995)

U.S. APPLICA	TION NO. (if known	, see 37 CFR 1.5	) INTERNATIONAL AI PCT/IB2005		ATTORNEY'S DOO PC261	
20. Other items or information: Certificate of Express Mail						
The fol	lowing fees have b	een submitted			CALCULATIONS	PTO USE ONLY
21. 🗸 Bas	21. Sasic national fee (37 CFR 1.492(a))\$300			\$ 300.00		
22. Examination fee (37 CFR 1.492(c))  If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)				\$ 200.00		
23.  Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1).4(4)			s 500.00			
	TOTAL OF 21, 22	2 and 23 =			1,000.00	
sequence electroni	Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).  The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
213 - 100 =	150 <sub>/50 =</sub>		3	×\$250	\$ 750.00	1
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				s		
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$	
Total claims	- 10	- 20 =	0	x \$50	\$ 0.00	
Independent clair	ms 2	-3=	0	× \$200	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360				\$		
TOTAL OF ABOVE CALCULATIONS =				\$ 750.00		
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.						
SUBTOTAL =			\$ 1,750.00			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).			\$			
TOTAL NATIONAL FEE =			\$ 1,750.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31), \$40.00 per property			s			
TOTAL FEES ENCLOSED =			\$ 1,750.00	)		
			Amount to be refunded:	\$		
					Amount to be charged	s

PTC-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, 0/88 065-0021
U.S. Patent and Trademark Office; U.S. DFATTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a 🗌	A check in the amount of \$	_ to cover the above fees is encl	osed.		
b. 🔽	Please charge my Deposit Account No. 23-0455 A duplicate copy of this sheet is enclosed.	in the amount of \$1,750.0	to cover the above fees.		
c. 🗸	The Commissioner is hereby authorized to charge any Account No. 23-0455, A duplicate copy of this sh	additional fees which may be re- eet is enclosed.	uired, or credit any overpayment to Deposit		
d. 🗆	Fees are to be charged to a credit card. WARNING: In be included on this form. Provide credit card information	formation on this form may beco tion and authorization on PTO-20	ne public. Credit card information should not l38.		
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filled and granted to restore the International Application to pending status.					
	LL CORRESPONDENCE TO:	$\bigcap$	h/bly		
Custo	mer No. 28880	Csigna David R	TURE V Kurlandsky		
Pfizer,	, Inc.	NAME.	Kullaliusky		
	Plymouth Road	41,505			
Ann A	rbor, Michigan 48105	REGIS	RATION NUMBER		
			•		